WCM
PGNX

Weld Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Weld Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-13,017
Closed -$80K – 1099
2019
Q2 		$80K Buy
+13,017
New +$62.8K 0.01% 699

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Weld Capital Management's PGNX Position: Q3 2019 in Review

Weld Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2019, closing a stake of 13,017 shares — an estimated $80K sold.

Weld Capital Management first reported a position in PGNX in Q2 2019 and held it in 1 quarter. The position peaked at $80K in Q2 2019. 135 funds tracked by Wall St. Rank hold PGNX as of Q3 2019.

  • Weld Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2019 after selling out during the quarter.
  • Weld Capital Management sold 13,017 Progenics Pharmaceuticals Inc shares in Q3 2019, an estimated $80K.
  • Weld Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2019 and held it in 1 quarter.
  • Weld Capital Management's Progenics Pharmaceuticals Inc position peaked at $80K in Q2 2019.
  • 135 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2019.

Based on Weld Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.